European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
FOSTER CITY, Calif.–(BUSINESS WIRE)– – In Clinical Trials, Biktarvy Demonstrated High Efficacy and Zero Resistance Through 48 Weeks – Gilead Sciences, Inc. (NASDAQ: GILD) today...